Three Biotech stocks – Bionomics, Mesoblast & CSL

BNC210 data demonstrates it as a novel treatment: Recently, Bionomics Limited (ASX: BNO) presented its BNC210 data at the Society of Biological Psychiatry Annual Convention in May 2017 in San Diego, CA. The data highlights a successful Phase 2 double-blinded, placebo controlled clinical trial in Generalized Anxiety Disorder (GAD) patients evaluating the effects of BNC210 on task-related brain activity and behavior associated with anxiety. This study used the anxiety provoked emotional faces task during functional magnetic resonance imaging (fMRI) scanning and evaluated defensive behavior using the Joystick Operated Runway Task (JORT). Amygdala hyperactivity has been associated with GAD and other anxiety related disorders. It is also associated with stress and trauma related conditions such as Post Traumatic Stress Disorder (PTSD). Anxiolytic drugs including the benzodiazepines, have been shown to diminish this hyperreactivity, suggesting that normalization of amygdala activity is critical to successful treatment of symptoms. Importantly, the data demonstrate that BNC210 treatment reduced bi-lateral amygdala reactivity to fearful faces relative to placebo. Additional analysis of the data also showed that connectivity between the amygdala and the anterior cingulate cortex was reduced in patients treated with BNC210. The results of this clinical trial indicate that BNC210 reduces activation of anxiety-related neural circuits and reduces anxiety-related behaviors. Notably, this highlights the potential of BNC210 as a novel treatment for patients who are suffering with GAD and other anxiety related disorders and suggests a role for BNC210 in the treatment of stress and trauma related disorders.   

To read the complete report CLICK HERETo get your free report CLICK HERE






 Disclaimer DisclaimerThe advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.CopyrightCopyright © 2015 Kalkine Pty Ltd ABN 34 154 808 312. No part of this website, or its content, may be reproduced in any form without the prior consent of Kalkine Pty Ltd.Kalkine is a trading name of Kalkine Pty Ltd ABN 34 154 808 312, which holds Australian Financial Services Licence No. 425376.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s